Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Liver metastases are associated with significantly reduced survival in patients with mUC receiving immunotherapy. However, both pembrolizumab and avelumab demonstrated improved outcomes compared with historical chemotherapy data. These findings underscore the need for personalized treatment strategies in high-risk subgroups.
Authors
- Kirstin Binz (ORCID: https://orcid.org/0000-0001-6189-9257)
- Martina Catalano (ORCID: https://orcid.org/0000-0003-1856-2848)
- Zin Myint (ORCID: https://orcid.org/0000-0002-3479-4203)
- F. Morelli
- Andrey Coatrini Soares (ORCID: https://orcid.org/0000-0003-4601-3555)
- Fabio Calabrò (ORCID: https://orcid.org/0000-0002-7863-3540)
- Hana Študentová (ORCID: https://orcid.org/0000-0003-2105-9258)
- Alonso-Gordoa Teresa
- Ravindran Kanesvaran (ORCID: https://orcid.org/0000-0002-2351-881X)
- Enrique Grande (ORCID: https://orcid.org/0000-0002-0134-4732)
- Inmaculada Orejana
- Francesco Massari (ORCID: https://orcid.org/0000-0001-6476-6871)
- Fernando Sabino Marques Monteiro (ORCID: https://orcid.org/0000-0002-6621-8251)
- Ondrej Fiala
- Alessia Mennitto (ORCID: https://orcid.org/0000-0002-3665-3295)
- Sebastiano Buti
- Deniz Tural
- Javier Molina-Cerrillo
- Linda Cerbone
- L. Formisano
- Alexandr Poprach
- Shilpa Gupta
- Tarek Taha
- Alina Pirstuk
- Renate Pichler
- Alessandro Rizzo
- Giandomenico Roviello
- Matteo Santoni
- Melichar Bohuslav
Institutions
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- University of Parma (IT)
- Cleveland Clinic (US)
- Royal Marsden NHS Foundation Trust (GB)
- Innsbruck Medical University (AT)
- Charles University (CZ)
- Casa Sollievo della Sofferenza (IT)
- Hospital Israelita Albert Einstein (BR)
- Cancer Institute (WIA) (IN)
- Markey Cancer Center (US)
- Eastern Cooperative Oncology Group (US)
- Kochi Medical School Hospital (JP)
- Institute of Cancer Research (CA)
- ASL Roma (IT)
- The University of Kansas Cancer Center (US)
- University Hospital in Motol (CZ)
- Masaryk Memorial Cancer Institute (CZ)
- Federico II University Hospital (IT)
- Azienda Ospedaliero Universitaria Maggiore della Carita (IT)
- Istituto Tumori Bari (IT)
- National Cancer Centre Singapore (SG)
- Hospital Sírio-Libanês (BR)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- MD Anderson Cancer Center Madrid (ES)
- Hospital Universitario Ramón y Cajal (ES)
- University of Florence (IT)
- University of Macerata (IT)
- Palacký University Olomouc (CZ)
- University of Bologna (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-24
- DOI
- https://doi.org/10.3389/fimmu.2026.1667155
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00